Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

The association of p53 expression levels with clinicopathological features and prognosis of patients with colon cancer following surgery.

Cao DZ, Ou XL, Yu T.

Oncol Lett. 2017 May;13(5):3538-3546. doi: 10.3892/ol.2017.5929. Epub 2017 Mar 27.

2.

Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer.

Jia X, Shanmugam C, Paluri RK, Jhala NC, Behring MP, Katkoori VR, Sugandha SP, Bae S, Samuel T, Manne U.

Oncotarget. 2017 Mar 21;8(12):20198-20212. doi: 10.18632/oncotarget.15560.

3.

NDRG2 gene copy number is not altered in colorectal carcinoma.

Lorentzen A, Mitchelmore C.

World J Clin Oncol. 2017 Feb 10;8(1):67-74. doi: 10.5306/wjco.v8.i1.67.

4.

Clinical Significance and Prognostic Relevance of Microsatellite Instability in Sporadic Colorectal Cancer Patients.

Copija A, Waniczek D, Witkoś A, Walkiewicz K, Nowakowska-Zajdel E.

Int J Mol Sci. 2017 Jan 6;18(1). pii: E107. doi: 10.3390/ijms18010107. Review.

5.

Large-Scale Analysis of Gene Expression Data Reveals a Novel Gene Expression Signature Associated with Colorectal Cancer Distant Recurrence.

Alajez NM.

PLoS One. 2016 Dec 9;11(12):e0167455. doi: 10.1371/journal.pone.0167455. eCollection 2016.

6.

Gasdermin C Is Upregulated by Inactivation of Transforming Growth Factor β Receptor Type II in the Presence of Mutated Apc, Promoting Colorectal Cancer Proliferation.

Miguchi M, Hinoi T, Shimomura M, Adachi T, Saito Y, Niitsu H, Kochi M, Sada H, Sotomaru Y, Ikenoue T, Shigeyasu K, Tanakaya K, Kitadai Y, Sentani K, Oue N, Yasui W, Ohdan H.

PLoS One. 2016 Nov 11;11(11):e0166422. doi: 10.1371/journal.pone.0166422. eCollection 2016.

7.

A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.

Niedzwiecki D, Hasson RM, Lenz HJ, Ye C, Redston M, Ogino S, Fuchs CS, Compton CC, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS, Bertagnolli MM.

Oncologist. 2017 Jan;22(1):107-114. doi: 10.1634/theoncologist.2016-0215. Epub 2016 Nov 7.

PMID:
27821793
8.

Commentary: Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer.

Bauer J, Staudacher JJ, Krett NL, Jung B.

J Rare Dis Res Treat. 2016;1(1):43-45. No abstract available.

9.

Advances in Biomarkers: Going Beyond the Carcinoembryonic Antigen.

Lopez NE, Peterson CY.

Clin Colon Rectal Surg. 2016 Sep;29(3):196-204. doi: 10.1055/s-0036-1584289. Review.

PMID:
27582644
10.

A 12-gene signature to distinguish colon cancer patients with better clinical outcome following treatment with 5-fluorouracil or FOLFIRI.

Paquet ER, Cui J, Davidson D, Pietrosemoli N, Hassan HH, Tsofack SP, Maltais A, Hallett MT, Delorenzi M, Batist G, Aloyz R, Lebel M.

J Pathol Clin Res. 2015 Apr 9;1(3):160-72. doi: 10.1002/cjp2.17. eCollection 2015 Jul.

11.

Multi-omics landscapes of colorectal cancer subtypes discriminated by an individualized prognostic signature for 5-fluorouracil-based chemotherapy.

Tong M, Zheng W, Li H, Li X, Ao L, Shen Y, Liang Q, Li J, Hong G, Yan H, Cai H, Li M, Guan Q, Guo Z.

Oncogenesis. 2016 Jul 18;5(7):e242. doi: 10.1038/oncsis.2016.51.

12.

Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.

Lee V, Murphy A, Le DT, Diaz LA Jr.

Oncologist. 2016 Oct;21(10):1200-1211. Epub 2016 Jul 13. Review.

PMID:
27412392
13.

The Dual Role of TGFβ in Human Cancer: From Tumor Suppression to Cancer Metastasis.

Lebrun JJ.

ISRN Mol Biol. 2012 Dec 24;2012:381428. doi: 10.5402/2012/381428. eCollection 2012. Review.

14.

Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients' survival? A pilot study on relevant mechanism.

Wei Z, Cao S, Liu S, Yao Z, Sun T, Li Y, Li J, Zhang D, Zhou Y.

Oncotarget. 2016 Jul 19;7(29):46158-46172. doi: 10.18632/oncotarget.10064.

15.

GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.

Lin WR, Chiang JM, Liang KH, Lim SN, Lai MW, Tsou YK, Hsieh TY, Hsu CK, Yeh CT.

Medicine (Baltimore). 2016 Apr;95(17):e3487. doi: 10.1097/MD.0000000000003487.

16.

A meta-analysis of MSI frequency and race in colorectal cancer.

Ashktorab H, Ahuja S, Kannan L, Llor X, Ellis NA, Xicola RM, Laiyemo AO, Carethers JM, Brim H, Nouraie M.

Oncotarget. 2016 Apr 23;7(23):34546-57. doi: 10.18632/oncotarget.8945.

17.

The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.

He EY, Hawkins NJ, Mak G, Roncolato F, Goldstein D, Liauw W, Clingan P, Chin M, Ward RL.

Oncologist. 2016 May;21(5):618-25. doi: 10.1634/theoncologist.2015-0530. Epub 2016 Mar 23.

18.

Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances.

Lech G, Słotwiński R, Słodkowski M, Krasnodębski IW.

World J Gastroenterol. 2016 Feb 7;22(5):1745-55. doi: 10.3748/wjg.v22.i5.1745. Review.

19.

Circadian gene expression predicts patient response to neoadjuvant chemoradiation therapy for rectal cancer.

Lu H, Chu Q, Xie G, Han H, Chen Z, Xu B, Yue Z.

Int J Clin Exp Pathol. 2015 Sep 1;8(9):10985-94. eCollection 2015.

20.

Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?

Lin AY, Lin E.

J Hematol Oncol. 2015 Nov 5;8:124. doi: 10.1186/s13045-015-0222-5.

Supplemental Content

Support Center